Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Polycystic Ovarian Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Polycystic Ovarian Syndrome - Overview 8 Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9 Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10 Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Polycystic Ovarian Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Polycystic Ovarian Syndrome - Products under Development by Companies 15 Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 16 Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 17 Addex Therapeutics Ltd 17 Crinetics Pharmaceuticals, Inc. 18 EffRx Pharmaceuticals S.A. 19 Euroscreen S.A. 20 Merck KGaA 21 Vicore Pharma AB 22 Polycystic Ovarian Syndrome - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 C-21 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 choriogonadotropin alfa - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ESN-364 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 JDSCR-004 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 KDT-501 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 metformin hydrochloride - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 MLE-4901 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Polycystic Ovarian Syndrome - Recent Pipeline Updates 45 Polycystic Ovarian Syndrome - Dormant Projects 47 Polycystic Ovarian Syndrome - Discontinued Products 48 Polycystic Ovarian Syndrome - Product Development Milestones 49 Featured News & Press Releases 49 Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 49 Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 49 Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 50 Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 50 Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 51 Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations 51 Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54

List of Tables Number of Products under Development for Polycystic Ovarian Syndrome, H1 2016 8 Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H1 2016 17 Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 18 Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H1 2016 19 Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H1 2016 20 Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H1 2016 21 Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 45 Polycystic Ovarian Syndrome - Dormant Projects, H1 2016 47 Polycystic Ovarian Syndrome - Discontinued Products, H1 2016 48 List of Figures Number of Products under Development for Polycystic Ovarian Syndrome, H1 2016 8 Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Targets, H1 2016 24 Number of Products by Stage and Targets, H1 2016 24 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30

Addex Therapeutics Ltd Crinetics Pharmaceuticals, Inc EffRx Pharmaceuticals S.A. Euroscreen S.A. Merck KGaA Vicore Pharma AB